CytoDyn Inc., a biotechnology company focused on the clinical development and potential commercialization of its product candidate, leronlimab, has released its Form 10-Q report for the quarter ended August 31, 2024. The report highlights significant financial improvements, strategic initiatives, and ongoing challenges as the company advances its clinical development programs.
Financial Highlights Total operating expenses : $(22.4) million, reflecting a significant decrease primarily due to a return of clinical expenses related to the settlement of the Company’s litigation with Amarex.
Operating gain (loss) : $22.4 million, a substantial improvement from the previous period’s loss of $(4.6) million. Net income […]
Full Post at www.tradingview.com